• Skip to main content
  • Skip to footer

Cellatrix

  • HOME
  • CONCEPT
  • PRODUCTS
  • SERVICE TO PHARMA

The Source, Washington University in Saint Louis

November 20, 2015 By Cellatrix

A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer. The process also may aid patients with leukemia or lymphoma.

https://source.wustl.edu/2015/11/personalized-drug-screening-on-horizon-for-multiple-myeloma-patients/

Derived news

  • https://www.sciencedaily.com/releases/2015/11/151120104008.htm
  • http://adcreview.com/news/cutting-edge-science-personalized-drug-screening-for-multiple-%E2%80%8Bmyeloma%E2%80%8B/
  • http://www.oncologynurseadvisor.com/multiple-myeloma/personalized-drug-screen-aids-treatment-selection-for-patients-with-multiple-myeloma/article/457948/
  • http://morningsignout.com/personalized-drug-screening-for-multiple-myeloma/
  • http://www.firstwordpharma.com/node/1334091#axzz40e6OAUDH
  • http://anothersample.net/3d-tissue-engineered-bone-marrow-as-a-novel-model-to-study-pathophysiology-and-drug-resistance-in-multiple-myeloma

Filed Under: News

Footer

About Us

Cellatrix LLC is a biotechnology company in Saint Louis, Missouri. Its mission is focused on the development of science, research involving both basic and translational approaches, and drug development for the ultimate goal of patient care.

Partnership

Cellatrix is in partnership with:
  • Azab Lab/ Washington University in St. Louis
  • Biogenerator
More information

Contact Us

Cellatrix LLC
4320 Forest Park Ave, Suite 303
St Louis, MO 63108, USA
Email
314-740-1870
News & Publications

Copyright © 2023 Cellatrix.com · Powered by NeuConcept · Log in